China Resources Sanjiu Secures Eight Classical Formula Approvals, Four as Domestic First
China Resources Sanjiu has secured approvals for eight classical formula compound preparations, four of which are the first in China. Wengjing Tang granules have been included in the national medical insurance catalog, covering 33 drug listing platforms and more than 50 medical institutions, while Shaoyao Gancao Tang granules obtained marketing approval in Macau. The company, a central state-owned pharmaceutical firm, began research in 2011 and has collaborated on a national key laboratory. As of June 2026, 47 classical formula preparations have been approved nationwide.
As of June 2026, 47 classical formula compound preparations had been approved for marketing nationwide. The state has continued to optimize the review and approval mechanism for classical formulas, systematically advancing textual research on ancient prescriptions and the construction of industry standards, providing institutional support for the modern transformation of ancient formulas. In this context, central state-owned pharmaceutical enterprises, leveraging their resource and technology advantages, have become an important force in the industrialization of classical formulas.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Traditional Chinese Medicine, with intensity 60/100 and 75% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.